Institute for Risk Assessment Sciences, Division of Environmental Epidemiology, Utrecht University, Jenalaan 18D, 3584 CK Utrecht, The Netherlands.
Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1925-7. doi: 10.1158/1055-9965.EPI-11-0396. Epub 2011 Jul 22.
Elevated circulating soluble CD30 (sCD30) has been previously associated with AIDS-related non-Hodgkin lymphoma (NHL) risk. This finding was recently extended to the general population where elevated levels of sCD30 were reported in prediagnostic serum among subjects that developed NHL later in life.
We carried out a replication study within the Italian European Prospective Investigation into Cancer and Nutrition cohort. Plasma sCD30 concentration was measured by ELISA in prospectively collected blood of 35 B-cell lymphoma cases and 36 matched controls.
We observed significantly increased relative risks for lymphoma with increasing sCD30 levels [OR (95% CI) for second and third tertiles vs. first tertile: 5.5 (1.5-20.2), 4.0 (1.1-13.9), respectively]. In addition, spline analyses showed that the dose-response curve of sCD30 and lymphoma risk was monotonic and quite similar to the risks reported in the previous study.
This replication study adds to the evidence that sCD30 is related to future lymphoma risk in a concentration-dependent manner in the general population.
The results of this study strengthen the observation that chronic sustained B-cell activation plays an important role in lymphomagenesis.
循环中可溶性 CD30（sCD30）水平升高与艾滋病相关非霍奇金淋巴瘤（NHL）风险相关。最近，这一发现被扩展到了普通人群中，在这些人群中，后来在生活中患上 NHL 的患者在预测性血清中报告了高水平的 sCD30。
我们在意大利欧洲前瞻性癌症和营养研究队列中进行了一项复制研究。通过 ELISA 测量前瞻性采集的 35 例 B 细胞淋巴瘤病例和 36 例匹配对照的血浆 sCD30 浓度。
我们观察到 sCD30 水平升高与淋巴瘤的相对风险显著增加[第二和第三三分位相对于第一三分位的比值比（95%CI）：5.5（1.5-20.2），4.0（1.1-13.9）]。此外，样条分析表明，sCD30 与淋巴瘤风险的剂量-反应曲线呈单调递增，与之前研究报告的风险相当相似。
这项复制研究增加了证据，表明 sCD30 与普通人群中未来淋巴瘤风险呈浓度依赖性相关。
本研究的结果加强了这样一种观察，即慢性持续的 B 细胞激活在淋巴瘤的发生中起着重要作用。
